Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 12:23 AM
Study NCT ID:
NCT07459504
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-09
First Post:
2026-02-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SMART Diets for MASLD
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR'], 'maskingDescription': 'Due to the nature of the treatment, it is not realistic to blind the treatment to either staff or patients and their caregivers. To mitigate the risk of bias associated with an unblinded study, all study team members will remain blinded to aggregate study results and only select members of the study team responsible for interim monitoring will have access to these data'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'Sequential, multiple-assignment randomized trial'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 102}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-04-26', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-03', 'completionDateStruct': {'date': '2030-12-26', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-03-05', 'studyFirstSubmitDate': '2026-02-17', 'studyFirstSubmitQcDate': '2026-03-05', 'lastUpdatePostDateStruct': {'date': '2026-03-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-03-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-12-26', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in hepatic steatosis', 'timeFrame': 'Baseline to 24 weeks', 'description': 'Change in hepatic steatosis by magnetic resonance imaging (MRI)'}], 'secondaryOutcomes': [{'measure': 'Change in fasting triglyceride', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in triglyceride in mg/dL'}, {'measure': 'Change in HDL', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in HDL mg/dL'}, {'measure': 'Change in VLDL-triglyceride', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Very-low-density-lipoprotein triglyceride'}, {'measure': 'Change in Waist circumference', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in Waist circumference in cm'}, {'measure': 'Change in body weight', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in weight in kilograms'}, {'measure': 'Change in BMI Z Score', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in body mass index z-score'}, {'measure': 'Change in Alanine Aminotransferase (ALT)', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in ALT'}, {'measure': 'Aspartate Aminotransferase (AST)', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in AST'}, {'measure': 'Gamma glutamyl transferase (GGT)', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in GGT'}, {'measure': 'Systolic blood pressure', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in systolic blood pressure mg/dL'}, {'measure': 'Diastolic blood pressure', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in diastolic blood pressure (mg/dL)'}, {'measure': 'Hemoglobin A1c', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in hemoglobin A1c'}, {'measure': 'HOMA-IR', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Change in homeostatic model assessment of insulin resistance (HOMA-IR)'}, {'measure': 'Adverse events', 'timeFrame': 'Baseline, 12 and 24 weeks', 'description': 'Number of adverse events compared between arms of the study'}, {'measure': 'Percent responders', 'timeFrame': 'Baseline to 24 weeks', 'description': 'Percent of participants who reduce hepatic steatosis in the group that start with low sugar diet compared to the group that starts with EAA intervention'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['MASLD', 'Adolescents', 'Liver', 'Sugar', 'Amino acid supplement'], 'conditions': ['Metabolic-dysfunction Associated Steatotic Liver Disease']}, 'descriptionModule': {'briefSummary': 'This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids (EAA) and/or Low Sugar Diet for children with metabolic dysfunction associated steatotic liver disease (MASLD) and increased cardiometabolic risk. The basis for the trial includes high-quality pilot data in both EAA for hepatic steatosis and a low sugar diet for hepatic steatosis. In the trial, children aged 11-17 years old will be eligible to participate if their BMI is greater than or equal to 95th% at baseline and hepatic steatosis is greater than or equal to 8% at baseline by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) because this is the most common age group diagnosed with metabolic-dysfunction associated steatotic liver disease.', 'detailedDescription': 'Metabolic-dysfunction associated steatotic liver disease is defined as the presence of abnormal hepatic stored triglycerides (hepatic steatosis), with one or more of 5 cardiometabolic factors (increased body mass index or waist circumference, hyperglycemia, hypertriglyceridemia, or low HDL) and no other chronic liver disease. Pediatric hepatic steatosis is central to long-term metabolic and cardiovascular health because of the relation of hepatic steatosis to the development of other major diseases. Hepatic steatosis limits the normal metabolic role of insulin and plays a key role in the future development of the metabolic syndrome, and is the strongest predictor for the development of type 2 diabetes.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '17 Years', 'minimumAge': '11 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Children 11 to 17-years-old at the time of consenting\n* Hepatic Steatosis by MRI greater than or equal to 8% on baseline MRI\n* At least 1 of the following cardiometabolic risk factors: BMI greater than or equal to 85th percentile for age/sex or WC greater than 95th percentile, Abnormal cholesterol or triglyceride levels, Blood pressure BP greater than or equal to 95th percentile OR greater than or equal to 130/80 and/or signs of insulin resistance (Acanthosis Nigricans OR HOMA-IR of greater 2.0 and greater 2.6 in prepubertal and pubertal children, respectively, Fasting Insulin Level of 10 pIU/mL in prepubertal children and of 17 pIU/mL and 13 pIU/mL in pubertal girls and boys, respectively, OR Prediabetes)\n* ALT greater than or equal to 40 U/L\n* Currently consumes greater than or equal to 2 eight-ounce sugar drinks (or juice) per week.\n* Patients of childbearing potential agrees to use adequate one or more effective methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n* Patients who are taking medications that can affect insulin (e.g., metformin, corticosteroids), most be on a stable dosage for at least 3 months prior to enrollment of the trial.\n* Written informed consent from parent or legal guardian, assent from child.\n\nExclusion Criteria:\n\n* Patients with Diagnosed Type 2 or Type 1 Diabetes Mellitus (T2DM) or HbA1c of \\>6.5 mg/dL at baseline\n* Patients diagnosed with or suspected to have a chronic liver disease other than MASLD by screening labs or evaluation (i.e autoimmune, viral). Screening labs are defined as: Hepatitis B surface antigen, Hepatitis C virus total antibody, IgG, ceruloplasmin, and alpha 1 antitrypsin phenotype.\n* Patients unable to complete MRI or Labs required for the study.\n* Current participation in another clinical trial\n* Current participation in a weight loss program or obesity treatment program or clinic\n* Cancer or history of cancer within 5 years\n* Severe illness that required hospitalization in the last 60 days\n* Use of medications known to cause liver steatosis (TPN, amiodarone, chronic oral steroids, etc.)\n* Patients with implanted metal devices that are not compatible with magnetic resonance imaging (MRI).\n* Intellectual disability or major psychiatric disorder limiting informed assent\n* Clinical evidence of cirrhosis or advanced liver disease by any one of the following abnormal labs: (Hemoglobin less than 10 g/dL, White blood cell less than 3,500 cells/mm, Neutrophil count less than 1,500 cells/mm3 of blood, Platelets less than 130,000 cells/mm3 of blood, Direct bilirubin greater than 1.0 mg/dL)\n* Elevated total bilirubin except if known to have Gilbert's syndrome and direct bilirubin in normal range.\n* Albumin less than 3.2 g/dL\n* A history of international normalized ratio (INR) greater than 1.4\n* AST or ALT greater than 250 IU/dL.\n* Compensated or decompensated cirrhosis with evidence of portal hypertension.\n* Patients is pregnant or breastfeeding.\n* Patients who have been enrolled in a recent clinical trial and had the last dose of investigational product within 30 days or 5 half-lives of the study drug, whichever is longer."}, 'identificationModule': {'nctId': 'NCT07459504', 'briefTitle': 'SMART Diets for MASLD', 'organization': {'class': 'OTHER', 'fullName': 'Corewell Health West'}, 'officialTitle': 'A Sequential Multiple Assignment Randomized Trial of Diet Treatments for Hepatic Steatosis and Cardiometabolic Risk in Youth', 'orgStudyIdInfo': {'id': 'CHW-2026-1283'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Essential Amino Acids Supplementation', 'description': 'The essential amino acid supplement contains the following formulation: histidine, isoleucine, leucine, lysine, phenylalanine, threonine, and valine. EAA, also called AMS2392 has been shown to decrease hepatic steatosis and lower circulating very-low-density lipoprotein triglyceride (VLDL-TG) concentrations through one or more of the following mechanisms: decreasing de novo lipogenesis; increasing hepatic and systemic fatty acid oxidation; increasing triglyceride secretion from the liver in the form of VLDL-TG; and increasing clearance of circulating VLDL-TG via activation of lipoprotein lipase.', 'interventionNames': ['Drug: Essential Amino Acids Supplementation intervention']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Low Sugar Diet', 'description': 'The Low Sugar Diet uses the adapted and extended Social Cognitive Theory (SCT) guided low sugar intervention that the Emory team previously developed. The registered dietitian nutritionist (RDN) helps families to identify foods high in sugar and to identify acceptable replacements in order to remove foods and drinks high in free sugar from the home and replacement with low or no free sugar containing similar foods.', 'interventionNames': ['Other: Low sugar diet']}], 'interventions': [{'name': 'Essential Amino Acids Supplementation intervention', 'type': 'DRUG', 'otherNames': ['EAA', 'AMS2392'], 'description': 'EAA supplement contains the following formulation: histidine, isoleucine, leucine, lysine, phenylalanine, threonine, and valine', 'armGroupLabels': ['Essential Amino Acids Supplementation']}, {'name': 'Low sugar diet', 'type': 'OTHER', 'description': 'The Low Sugar Diet uses the adapted and extended Social Cognitive Theory (SCT) guided low sugar intervention. The registered dietitian nutritionist (RDN) helps families to identify foods high in sugar and to identify acceptable replacements in order to remove foods and drinks high in free sugar from the home and replacement with low or no free sugar containing similar foods.', 'armGroupLabels': ['Low Sugar Diet']}]}, 'contactsLocationsModule': {'locations': [{'zip': '49503', 'city': 'Grand Rapids', 'state': 'Michigan', 'country': 'United States', 'contacts': [{'name': 'Yvonne Edgerly', 'role': 'CONTACT', 'email': 'Yvonne.Edgerly@corewellhealth.org', 'phone': '616-267-2100'}, {'name': 'Miriam B Vos, MD, MSPH', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Corewell Health West', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}], 'centralContacts': [{'name': 'Yvonne Edgerly', 'role': 'CONTACT', 'email': 'Yvonne.Edgerly@corewellhealth.org', 'phone': '616-267-2100'}], 'overallOfficials': [{'name': 'Miriam B Vos, MD, MSPH', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Corewell Health West and Michigan State University'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'The IPD will be available within one year of the publication of the results of the trial and will be hosted for at least 2 years.', 'ipdSharing': 'YES', 'description': 'The proposed research will include data from approximately 102 participants at up to 3 time-points. The final scientific datasets will include intervention assignment, anthropometrics, laboratory and imaging data. All protected health information and personally identified information will be removed. The study dates will be removed. Scientific data from the primary and secondary endpoints, along with a detailed data dictionary, and study protocols will be made available on a data repository such as Emory DataVerse. Genetic information for participants will not be made available.', 'accessCriteria': 'The Emory DataVerse is an open-source web application available to registered users.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Corewell Health West', 'class': 'OTHER'}, 'collaborators': [{'name': 'Van Andel Research Institute', 'class': 'OTHER'}, {'name': 'Emory University', 'class': 'OTHER'}, {'name': 'Michigan State University', 'class': 'OTHER'}, {'name': 'The Amino Company', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Miriam Vos', 'investigatorAffiliation': 'Corewell Health West'}}}}